With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.

The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug ...

High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

There is no FDA-approved generic version of brand-name weight loss drugs since pharmaceutical companies still hold patents on ...

Headlines,Novo Nordisk experienced a decline in stock value after recent news from its lab.,Eli Lilly, (NYSE:LLY),and Viking ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Headlines,UPS shares declined following FedEx's disappointing earnings report and lowered forecast.,Concerns arise regarding ...